OpenEvidence’s $12 billion valuation reflects investor confidence in its bottom-up, doctor-first model. It has driven rapid adoption, with more than 757,000 clinicians using the startup’s free AI medical search tool regularly. That scale is paired with targeted pharmaceutical advertising that’s already pushed the company past a $100 million revenue run rate.
Investors at Breyer Capital think 2026 could mark a turning point in digital health, as logistics become as important as scientific innovation. They highlighted three key trends shaping the market: shifting biotech constraints from biology to delivery, bottom-up product adoption by clinicians, and a wave of consolidation among AI startups.
Zelis highlights how employers, payers, and consumers are integrating digital tools to manage healthcare costs.
Matt Holt, former New Mountain Capital executive, is exploring a $30 billion deal to combine five health tech startups into a single platform called Thoreau. The venture would set out to simplify and integrate services across payers, providers and data — and if completed, it would rank among the largest private equity-backed health tech companies ever. Time will tell if this massive consolidation ever gets completed or translates into real value — or if it's just another bet on scale.
December has seen a slew of executive hires, promotions and layoffs across the healthcare industry. For instance, Breyer Capital, the FDA and Strive Health named new executives. There were also layoffs at organizations including Alameda Health System, Pfizer and Voyager Therapeutics.
In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workflows are streamlined and value is delivered across stakeholders. This will differentiate winning AI startups from incumbents and copycat competitors, said Morgan Cheatham, head of healthcare and life sciences at Breyer Capital.
In a webinar sponsored by fintech business Mercury, investors from Breyer Capital and MBX Capital shared their startup trend perspectives on AI, valuation, and alternative funding.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
A webinar scheduled for Thursday May 8 at 1 pm ET sponsored by Mercury will explore how early-stage medtech and biopharma investors are looking at the market and how they're advising startups in the wake of cuts to NIH and SBIR grants.
Scheduled for May 8 at 1 pm ET, the conversation will include Morgan Cheatham, head of healthcare and life sciences at Breyer Capital, Gurdane Bhutani, founder and managing partner of MBX Capital, and will be moderated by Mercury Head of Healthcare and Life Sciences Ben Kromnick.
April has seen a slew of executive hires, exits and layoffs across the healthcare industry. For example, AdventHealth and DexCare both named new CEOs, and Crozer Health and UNC Health have undergone CEO exits. There were also layoffs at organizations including Aetna, Sanford Health and Caribou Biosciences.
The company, whose technology won FDA Breakthrough Device designation earlier this year and which signed a deal with Philips earlier this month, plans to use the money to support FDA clearance and other efforts.
How to turn analytics into actual policy outcomes.
Investors such as Jim Breyer, Breyer Capital CEO, and Julian Robertson, who founded hedged fund Tiger Global Management, among other investors, led the round according to Fuchs.